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aripeddi_rk@yahoAbstract Two highly sensitive methods for the determination of genotoxic alkyl methane
sulfonates (AMSs) and alkyl paratoluene sulfonates (APTSs) in lamivudine using hyphenated
techniques have been presented. AMSs were determined by GC–MS method using GSBP-
INOWAX (30 m 0.25 mm 0.25 mm) column. Temperature program was set by maintaining at
100 1C initially for 3 min, then rised to 220 1C at the rate of 15 1C/min and maintained at 220 1C for
16 min. N,N-dimethyl formamide was used as diluent. APTSs were determined by LC-MS using
Zorbax, Rx C8, 250 mm 4.6 mm, 5 mm column as stationary phase. 0.01 M ammonium acetate is
used as buffer. The mixture of buffer and methanol in 75:25 (v/v) ratio was used as mobile phase A
and mixture of buffer and methanol in 5:95 (v/v) ratio was used as mobile phase B. The gradient
program (T/%B) was set as 0/28, 16/50, 17/100, 23/100, 27/28 and 40/28. Both the methods were
validated as per International Conference on Harmonization guidelines. Limit of quantitation was
found 1.5 mg/mL for AMSs and was in the range of 1.0–1.5 mg/mL for APTSs.
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o.com (K. Ramakrishna).1. Introduction
Synthesis of drug substances often involves the use of reactive
reagents and hence, these reagents may be present in the ﬁnal
drug substances as impurities. Such chemically reactive impu-
rities may have unwanted toxicities, including genotoxicity and
carcinogenicity and are to be controlled based on the max-
imum daily dose [1]. These limits generally fall at low mg/mL
levels and hence conventional HPLC, GC methods (or ﬁnal
drug substance methods) are not suitable for their determina-
tion. Hyphenated techniques like GC–MS and LC–MS com-
bine physical separation capabilities of chromatography (GC
or HPLC) with the mass analysis capabilities of mass
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conventional HPLC and GC methods. Their applications are
oriented towards the potential identiﬁcation and quantitation
of trace level of impurities in drug substances [2].
Lamivudine (LMD) is chemically known as (2R-Cis)-4-
Amino-1-[2-(hydroxy methyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimi-
dinone. It is used to treat HIV (Type 1) and hepatitis B [3]. In the
manufacturing process of LMD, methane sulfonic acid (MSA)
and paratoluene sulfonic acid (PTSA) are used as reagents and
three alcohols (viz. methanol, ethanol and isopropanol) are used
as solvents and hence genotoxic methyl methane sulfonate
(MMS), ethyl methane sulfonate (EMS) and isopropyl methane
sulfonate (IPMS), methyl paratoluene sulfonate (MPTS), ethyl
paratoluene sulfonate (EPTS) and isopropyl paratoluene sulfo-
nate (IPPTS) may exist as impurities in lamivudine drug
substance. Based on maximum daily dose of LMD (300 mg/
day), these are to be controlled at a limit of 5 mg/mL.
In literature, some analytical methods using hyphenated
techniques for the determination of AMSs [4–7], APTSs [5,6,8]
and LMD [9–13] were reported. However, no method was
reported for the determination of AMSs and APTSs in LMD.
Hence, the present work is aimed towards the development of
rapid, speciﬁc and robust methods for the determination of
AMSs and APTSs in LMD at trace level concentration.2. Experimental
2.1. Chemicals and reagents
MMS, EMS and IPMS were purchased from Acros organics,
Geel, Belgium. MPTS and EPTS were purchased from
Aarti Drugs Ltd., Mumbai, India. N,N-dimethyl formamide,
ammonium acetate, acetonitrile and methanol were procured
from Merck, India. IPPTS and pure samples of LMD were
obtained from synthetic division of Hetero Drugs Ltd. (R&D),
Hyderabad, India.
2.2. Preparation of stock solutions
N,N-dimethyl formamide was used as diluent in GC–MS
method. MMS, EMS and IPMS stock solutions were prepared
by dissolving 10 mg each individually in 10 mL of diluent. The
mixture solution, 1000 mg/mL with respect to 200 mg/mL of
LMD, was prepared by diluting the appropriate volumes of
above stock solutions with diluent.
The mixture of water and acetonitrile in the ratio of 65:35 v/
v was used as diluent in LC-MS method. MPTS, EPTS and
IPPTS stock solutions were prepared by dissolving 10 mg each
individually in 10 mL of diluent. The mixture solution,
1000 mg/mL with respect to 50 mg/mL of LMD, was prepared
by diluting the appropriate volumes of above stock solutions
with diluent as above. A blend solution was also prepared by
spiking 1000 mg/mL of APTSs to 50 mg/mL of LMD and is
used for method development.
2.3. GC–MS conditions
GC–MS analysis was carried out on GCMS-QP2010 system
(Shimadzu Corporation, Japan) having GCMS solution soft-
ware. The instrument was run in EI mode. GSBP-INOWAXcolumn (30 m 0.2 mm i.d. 0.25 mm ﬁlm, Agilent Technolo-
gies, USA) was used as stationary phase. 1.5 mL volume with 1:5
split inlet was selected for injection. The GC oven temperature
program was set by maintaining at 100 1C initially for 3 min,
then rised to 220 1C at the rate of 15 1C/min maintained at
220 1C for 16 min. The injection temperature, GC–MS interface
temperature and ion source temperature were 200, 240 and
240 1C, respectively. Helium was used as the carrier gas with a
ﬂow rate of 1.46 mL/min. The ionizing energy was 70 eV. The
mass detector gain is 1.5 kV.
2.4. LC–MS conditions
LC–MS analysis was carried out on Shimadzu LCMS-
2010 EV system (Shimadzu Corporation, Japan) having
LCMS solution software in electro spray ionization (positive)
mode. Zorbax, Rx C8 column (250 mm 4.6 mm, 5 mm,
Agilent Technologies, USA) was used as stationary phase.
0.01 M ammonium acetate is used as buffer. The mixture of
buffer and methanol in 75:25 (v/v) ratio was used as mobile
phase A and that of buffer and methanol in 5:95 (v/v) ratio
was used as mobile phase B. The gradient program (T/%B)
was set as 0/28, 16/50, 17/100, 23/100, 27/28 and 40/28. The
ﬂow rate of the mobile phase was kept at 1.0 mL/min. The
injection volume was set as 50 mL. Column oven temperature
and auto sampler temperature were set as 50 1C and 20 1C,
respectively. Interface, curve dissolvation line (CDL) and
detector voltages are 4.5 kV, 5.0 V and 1.75 kV, respectively.
Interface, CDL and heat block temperatures were 250, 250
and 200 1C, respectively. Nabulizing gas ﬂow was 1.5 L/min.3. Results and discussion
3.1. GC–MS method development
LMD is soluble in N,N-dimethyl formamide (DMF) and hence
it was used as diluent. AMSs mixture solution was initially run
through using DB-1 column (100%-Dimethylpolysiloxane). The
resolution between MMS and IPMS is not adequate in this
column. Then, this column was replaced by DB-5 column and
the same result was found. Finally, GSBP-INOWAX column
was used and good resolutions were observed. An optimum
injection volume of 1.5 mL was chosen. The split ratio was ﬁxed
as 1:5 depending on the detector response. An initial column
temperature of 100 1C was found to be optimum. The elution
order was observed from the total ion chromatogram (Fig. 1) in
SCAN mode using AMSs mixture (1.5 mg/mL each) and the
individuals were also conﬁrmed using the National Institute of
Standard Technology mass spectral library. Validation was done
in Selective Ion Monitoring (SIM) monitoring for m/z ions at
110 for MMS, 124 for EMS and 138 for IPMS.
3.2. LC–MS method development
A blend solution containing APTSs and LMD was run in
literature method [8]. LMD eluted too early and hence the ﬂow
rate of the mobile phase was reduced from 1.5 mL/min to 1.0 mL/
min. In this condition LMD eluted at an optimum retention time,
but the retention times of APTSs were drastically increased.
Hence, the gradient program (T/%B) was ﬁne tuned to 0/28,
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Figure 2 LC–MS total ion chromatogram of APTSs.
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Figure 1 GC–MS total ion chromatogram of AMSs.
N.V.V.S.S. Raman et al.31616/50, 17/100, 23/100, 27/28 and 40/28 and optimum retention
times were achieved for APTSs. The elution order was observed
from the total ion chromatogram (Fig. 2) in SCAN mode using
lamivudine solution spiked with MPTS (1.5 mg/mL), EPTS
(1.5 mg/mL) and IPPTS (1.0 mg/mL). Validation was done in
Selective Ion Monitoring (SIM) monitoring for [MþNH4]þ ions
at 204 for MPTS, 218 for EPTS and 232 for IPPTS.3.3. Method validation
The developed methods were validated as per ICH guidelines
[14] in terms of speciﬁcity, limit of detection (LOD), limit of
quantitation (LOQ), precision, linearity, accuracy, robustness
and system suitability and the data are presented in Table 1
(GC–MS) and Table 2 (LC–MS).
The speciﬁcity of the developed GC–MS and LC-MS
methods was indicated by showing the m/z peaks in GC–MS
method as 110 for MMS, 124 for EMS and 137 for IPMS and
[MþNH4]þ peaks as 204 for MPTS, 218 for EPTS and 232
for IPPTS.
In GC–MS method, AMSs solutions (1000 mg/mL each) with
respect to 200 mg/mL of LMD and in LC-MS method, APTSs
solutions (1000 mg/mL each) with respect to 50 mg/mL of LMD
were injected separately and S/N ratios were recorded. These
solutions were further diluted to achieve the signal-to-noise (S/N)ratios at about 3 and 10 for determining LOD and LOQ,
respectively for both the methods.
The precision of the methods was checked by injecting LOQ
solutions for six times. The values of RSDs for areas of each
AMSs (in GC–MS) and APTS (in LC–MS) were calculated.
The intermediate precision of the methods was also veriﬁed on
six different days in the same laboratory using the LOQ level
solutions. The low RSD values ensured the precision of the
developed methods.
Linearity test solutions for AMSs and APTSs were prepared
individually at six concentration levels in the range of LOQ to
120% of the speciﬁcation level viz. 5 mg/mL. LOQ and sixth
levels were injected six times and other four levels were injected
thrice. The average peak areas versus concentrations were
subjected to least-squares linear regression analysis. The derived
correlation coefﬁcients were above 0.995 indicating the best
ﬁtness of the linearity curves of the developed methods.
Standard addition experiments were conducted in triplicate
preparations to determine accuracy of the methods at LOQ
level and recoveries of all the genotoxins were determined. The
recoveries were found to be in the accepted range.
The robustness of GC–MS was illustrated by getting the
identical retention times and peak areas of AMSs in the varied
GC conditions of 75% on the carrier gas ﬂow, 75 1C on the
initial oven temperature,71 1C/min on the ramp rate. Similarly,
the robustness of LC–MS method was ensured by getting the
resolution between any two APTSs to be greater than 2.0, when
Table 1 Validation data of GC–MS method for the determination of MMS, EMS and IPMS.
Parameter MMS EMS IPMS
LOD (mg/mL) 0.5 0.5 0.5
LOQ (mg/mL) 1.5 1.5 1.5
Precision at LOQ level (RSD, %) 1.99 1.36 1.55
Precision at sixth level (RSD, %) 0.84 0.90 0.87
Intermediate precision at LOQ (RSD, %) 2.08 1.58 1.86
Linearity range (mg/mL) 1.5–6.0 1.5–6.0 1.5–6.0
Correlation coefﬁcient 0.999 0.999 0.999
Slope 60332 97982 73058
Intercept 1524 28001 13134
Accuracy at LOQ (recovery, %)
Preparation-1 102.0 102.4 95.0
Preparation-2 104.0 104.8 95.0
Preparation-3 105.3 106.4 107.1
Abbreviations:
MMS¼Methyl methane sulfonate,
EMS¼Ethyl methane sulfonate,
IPMS¼Isopropyl methane sulfonate.
Table 2 Validation data of LC–MS method for the determination of MPTS, EPTS and IPPTS.
Parameter MPTS EPTS IPPTS
LOD (mg/mL) 0.6 0.6 0.3
LOQ (mg/mL) 1.5 1.5 1.0
Precision at LOQ level (RSD, %) 1.60 1.62 1.20
Precision at sixth level (RSD, %) 0.70 0.71 1.80
Intermediate precision at LOQ (RSD, %) 1.14 1.89 1.35
Linearity range (mg/mL) 1.5–6.0 1.5–6.0 1.0–6.0
Correlation coefﬁcient 0.999 0.999 0.999
Slope 23310 23064 38099
Intercept 569 824 766
Accuracy at LOQ (recovery, %)
Preparation-1 98.1 101.6 101.0
Preparation-2 97.9 98.3 98.8
Preparation-3 94.5 103.3 102.7
Abbreviations:
MPTS¼Methyl paratoluene sulfonate,
EPTS¼Ethyl paratoluene sulfonate,
IPPTS¼Isopropyl paratoluene sulfonate.
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both mobile phases A and B (72%) and column temperature
(75 1C) were deliberately varied.
The solution stability of APTSs in diluent in LC–MS method
was determined by leaving APTSs mixture solution at speciﬁca-
tion level in a tightly capped volumetric ﬂask at room
temperature for 48 h and measuring the amounts of the APTSs
for every 6 h. All the APTSs were found to be stable up to 48 h.
The system suitability of both the methods was ensured by
getting the %RSD less than 10.0 for six injections of all the
AMSs in GC–MS method and APTSs in LC–MS method at
speciﬁcation level.4. Conclusions
GC–MS and LC–MS methods that can quantify genotoxic
alkyl methane sulfonates and alkyl para toluene sulfonates inlamivudine at trace level concentration have been developed
and validated as per ICH guidelines. The effectiveness of the
two methods was ensured by the speciﬁcity, precision, accu-
racy and robustness. Hence, both the methods well suits for
their intended purposes and can be successfully applied for the
release testing of lamivudine into the market.
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